Cystic fibrosis (CF) is an inherited disorder which results in increased thickness of secretions, especially in the lungs. By adulthood, the majority of patients with CF will have a bacteria living in their lungs, called Pseudomonas aeruginosa which can cause lung infections. This usually results in worsening respiratory symptoms and often an acute deterioration in their lung function. They are usually treated with antibiotics that target the Pseudomonas aeruginosa. These antibiotics are typically given as short intravenous infusions several times a day. This study aims to compare the standard method of giving these antibiotics with a different strategy of giving these antibiotics to see if this can improve the outcomes of treatment of these infections and reduce the amount of Pseudomonas aeruginosa in the lungs of these patients. This strategy consists of giving the same antibiotics continuously, to ensure there is always enough antibiotic in the bloodstream and the lung to be able to kill the bacteria.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
50
Ceftazidime 1g q8/24
Ceftazidime loading dose 1g infused over 30mins then 3g infused over 12h q12/24
Meropenem 1g q8/24, infusion over 30 minutes
Meropenem initial loading dose of 500mg infused over 30 minutes followed by 1.5g infused over 12/24, q12/24
Ticarcillin/clavulanate 3.1g q6/24
Ticarcillin-clavulanate loading dose 1.55g followed by 12.4g infused over 24/24 q24/24
Cefepime 1g q8/24
Cefepime loading dose 500mg followed by 1.5g infused over 12/24, q12/24
Piperacillin tazobactam loading dose of 4.5g infused over 30 minutes followed by 18g infused over 24/24, q24/24
Piperacillin tazobactam 4.5g q6/24
The Alfred Hospital
Melbourne, Victoria, Australia
Cystic Fibrosis Questionnaire-Revised respiratory component (CFQ-R) respiratory symptom score
Time frame: Day 0 to Day 14
Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) respiratory symptom score
Time frame: Day 0 to Day 7, Day 0 to Day 28
Lung function testing; Forced volume expired in one second (FEV1)
Time frame: Day 0 to Day 7, Day 0 to Day 28
C-reactive peptide (CRP)
Time frame: Day 0 to Day 3
Quantitative bacterial load in sputum (total + Pseudomonas aeruginosa)
Measured by PCR.
Time frame: Day 0 to Day 3, Day 0 to Day 7
Time above minimum inhibitory concentration (MIC)
Time frame: Day 3
Antibiotic stability
For ceftazidime and meropenem, antibiotic levels will be measured from the infusion bag at the beginning and end of the infusion to determine the amount of degradation of these antibiotics. The temperature of the infusion bags will be monitored continuously during this time.
Time frame: Day 3
Pseudomonas aeruginosa virulence gene determinants
A panel of different previously identified virulence gene determinants for Pseudomonas aeruginosa will be measured by RNA analysis.
Time frame: Day 0 to Day 3 and Day 0 to Day 7
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.